Novo Nordisk's new obesity drug Wegovy certainly seems to have gotten off to a great start in the US following its approval from the US Food and Drug Administration (FDA) in early June.
Over the course of the first five weeks, more than 8,000 prescriptions have been issued for the new obesity drug, which is based around the GLP-1 analog semaglutide. This is a significantly faster development than what Novo Nordisk's other drug Saxenda went through, which was launched in 2015. It is based on the substance liraglutide, which is a predecessor to semaglutide.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
CHMP recommends nine new drugs, rejects one
Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.
WS Audiology still chewing over listing of online hearing company
The hearing giant is still mulling over the independent listing of Hear.com.
CEO at WSA: No clarity on EQT exit plans yet
The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.
Oticon: Covid-19 led to debates about product launches
The unpredictable world situation in the spring of 2020 meant that the timing of product launches was frequently discussed at Demant-owned Oticon, located in Denmark.
EU Commission ends Danish HERA dreams – but could provide new opportunities for the pharmaceutical industry
With a budget potentially exceeding EUR 47.1bn (DKK 350bn), the EU Commission wants to establish a new agency to ward against future health crises. While the financial makeup is uncertain, good news for future clinical trials might be on the way.
Formulation Development Specialist – Product Lifecycle Management (PLM), Orifarm 
Scientist, Adcendo ApS 
Principal Scientist, In Vivo Pharmacology 
Director of Communications – Evaxion Biotech 
Associate Director/Senior Manager, Global Regulatory Affairs Project Lead - Genmab 
Senior Clinical Research Specialist - Ambu 
Associate Director, PV QA - Y-mAbs Therapeutics 
Medical Scientific Liaison Dermo aesthetic, IBSA 
Scientific Advisor infectious disease - Vaccibody 
Employee of the regulatory department with knowledge of food safety and legislation within dietary supplements and medicines 
KLIFO is looking for a talented Medical Writer (DK, SE or DE)